1
|
Bhattacharya S, Page A, Shinde P. Capecitabine loaded potato starch-chitosan nanoparticles: A novel approach for targeted therapy and improved outcomes in aggressive colon cancer. Eur J Pharm Biopharm 2024; 200:114328. [PMID: 38763329 DOI: 10.1016/j.ejpb.2024.114328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 05/08/2024] [Accepted: 05/14/2024] [Indexed: 05/21/2024]
Abstract
Aggressive colon cancer treatment poses significant challenges. This study investigates the potential of innovative carbohydrate-based nanoparticles for targeted Capecitabine (CTB) delivery. CTB nanoparticles were synthesized by conjugating CTB with potato starch and chitosan using ultrasonication, hydrolysis, and ionotropic gelation. Characterization included drug loading, rheology, Surface-Enhanced Raman Spectroscopy (SERS), Fourier-Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Thermogravimetric Analysis (TGA). In vitro and in vivo antitumor activity was evaluated using HT-29 cells and N, N-dimethylhydrazine-induced Balb/c mice, respectively. Cellular assays assessed angiogenesis, migration, proliferation, and apoptosis. Nanoparticles exhibited a mean size of 245 nm, positive zeta potential (+30 mV), high loading efficacy (76 %), and sustained drug release (92 % over 100 h). CTB-loaded nanoparticles displayed superior colon histology, reduced tumour scores, and inhibited VEGD and CD31 expression compared to free CTB. Cellular assays confirmed significant antitumor effects, including reduced tube formation, migration, and proliferation, and increased apoptosis. This study demonstrates the promise of CTB-loaded potato starch-chitosan nanoparticles for aggressive colon cancer treatment. These findings highlight the potential of these nanoparticles for further evaluation in diverse cancer models.
Collapse
Affiliation(s)
- Sankha Bhattacharya
- Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India.
| | - Amit Page
- Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India
| | - Prafull Shinde
- Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, NMIMS Deemed-to-be-University, India
| |
Collapse
|
2
|
Tan MF, Hosier BM, Forsythe NL, Maynard HD. Enzyme-Polymer Conjugates with Photocleavable Linkers for Control Over Protein Activity. Polym Chem 2024; 15:1085-1092. [PMID: 38854662 PMCID: PMC11155517 DOI: 10.1039/d3py01339a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2024]
Abstract
Reversible conjugation of polymers to proteins is important for a variety of applications, for example to control protein activity. Light is often employed as an external trigger to allow for spatio and temporal control over release of a payload. In this report, we demonstrate preparation of photocleavable poly(polyethylene glycol) acrylate)-lysozyme (pPEGA-Lys) conjugates via ortho-nitrobenzyl linkages. The conjugates were made by both grafting-to and grafting-from in order to compare and contrast the two synthetic approaches. First, a lysine-reactive ortho-nitrobenzyl atom transfer radical polymerization (ATRP) initiator was synthesized. For the grafting-to strategy, the initiator was employed in the ATRP of PEGA, and the subsequent polymer was conjugated to the lysine residues of lysozyme. For the grafting-from strategy, lysozyme was modified first with the photocleavable initiator, and the purified macroinitiator was then subjected to polymerization conditions to synthesize the protein-polymer conjugate. The polymer was cleaved from the protein via UV light, and activity before and after polymer removal was evaluated, showing 83% recovery. This work provides evidence that reversing conjugation is successful for activity modulation for ortho-nitrobenzyl linked protein-polymer conjugates.
Collapse
Affiliation(s)
- Mikayla F Tan
- Department of Chemistry and Biochemistry and California NanoSystems Institute, 607 Charles E. Young Drive East, University of California, Los Angeles, CA 90095-1569, USA
| | - Brock M Hosier
- Department of Chemistry and Biochemistry and California NanoSystems Institute, 607 Charles E. Young Drive East, University of California, Los Angeles, CA 90095-1569, USA
| | - Neil L Forsythe
- Department of Chemistry and Biochemistry and California NanoSystems Institute, 607 Charles E. Young Drive East, University of California, Los Angeles, CA 90095-1569, USA
| | - Heather D Maynard
- Department of Chemistry and Biochemistry and California NanoSystems Institute, 607 Charles E. Young Drive East, University of California, Los Angeles, CA 90095-1569, USA
| |
Collapse
|
3
|
Bhattacharya S, Prajapati BG, Singh S. A critical review on the dissemination of PH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy. Crit Rev Oncol Hematol 2023; 185:103961. [PMID: 36921781 DOI: 10.1016/j.critrevonc.2023.103961] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 03/08/2023] [Accepted: 03/10/2023] [Indexed: 03/16/2023] Open
Abstract
Stimuli-responsive nanocarriers have the potential to revolutionize cancer treatment by allowing precise delivery of drugs to the site of disease. The use of polymeric nanocarriers with surfaces that respond to triggers such as pH, light, temperature, and redox potential enables targeted drug distribution. pH is a particularly useful tool, as the lower pH in tumour microenvironments can trigger changes in drug release. Recent advances in the development of pH-responsive polymer nanoparticles have shown great promise for improved in vivo drug delivery, reduced negative drug responses, and more precise drug distribution. A deeper understanding of these nanocarriers will allow us to overcome the challenges of targeted cancer treatment and create a better drug delivery system.
Collapse
Affiliation(s)
- Sankha Bhattacharya
- Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India.
| | - Bhuphendra G Prajapati
- Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, 22 Kherva, 384012, India
| | - Sudarshan Singh
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
| |
Collapse
|
4
|
Gelb M, Messina KMM, Vinciguerra D, Ko JH, Collins J, Tamboline M, Xu S, Ibarrondo FJ, Maynard HD. Poly(trehalose methacrylate) as an Excipient for Insulin Stabilization: Mechanism and Safety. ACS APPLIED MATERIALS & INTERFACES 2022; 14:37410-37423. [PMID: 35968684 PMCID: PMC9412841 DOI: 10.1021/acsami.2c09301] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Insulin, the oldest U.S. Food and Drug Administration (FDA)-approved recombinant protein and a World Health Organization (WHO) essential medicine for treating diabetes globally, faces challenges due to its storage instability. One approach to stabilize insulin is the addition of poly(trehalose methacrylate) (pTrMA) as an excipient. The polymer increases the stability of the peptide to heat and mechanical agitation and has a low viscosity suitable for injection and pumps. However, the safety and stabilizing mechanism of pTrMA is not yet known and is required to understand the potential suitability of pTrMA as an insulin excipient. Herein is reported the immune response, biodistribution, and insulin plasma lifetime in mice, as well as investigation into insulin stabilization. pTrMA alone or formulated with ovalbumin did not elicit an antibody response over 3 weeks in mice, and there was no observable cytokine production in response to pTrMA. Micropositron emission tomography/microcomputer tomography of 64Cu-labeled pTrMA showed excretion of 78-79% ID/cc within 24 h and minimal liver accumulation at 6-8% ID/cc when studied out to 120 h. Further, the plasma lifetime of insulin in mice was not altered by added pTrMA. Formulating insulin with 2 mol equiv of pTrMA improved the stability of insulin to standard storage conditions: 46 weeks at 4 °C yielded 87.0% intact insulin with pTrMA present as compared to 7.8% intact insulin without the polymer. The mechanism by which pTrMA-stabilized insulin was revealed to be a combination of inhibiting deamidation of amino acid residues and preventing fibrillation, followed by aggregation of inactive and immunogenic amyloids all without complexing insulin into its hexameric state, which could delay the onset of insulin activity. Based on the data reported here, we suggest that pTrMA stabilizes insulin as an excipient without adverse effects in vivo and is promising to investigate further for the safe formulation of insulin.
Collapse
Affiliation(s)
- Madeline
B. Gelb
- Department
of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States
| | - Kathryn M. M. Messina
- Department
of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States
| | - Daniele Vinciguerra
- Department
of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States
| | - Jeong Hoon Ko
- Department
of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States
| | - Jeffrey Collins
- Department
of Molecular and Medical Pharmacology and Crump Institute for Molecular
Imaging, David Geffen School of Medicine,
University of California, Los Angeles, California 90095-1735, United States
| | - Mikayla Tamboline
- Department
of Molecular and Medical Pharmacology and Crump Institute for Molecular
Imaging, David Geffen School of Medicine,
University of California, Los Angeles, California 90095-1735, United States
| | - Shili Xu
- Department
of Molecular and Medical Pharmacology and Crump Institute for Molecular
Imaging, David Geffen School of Medicine,
University of California, Los Angeles, California 90095-1735, United States
| | - F. Javier Ibarrondo
- Division
of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1569, United States
| | - Heather D. Maynard
- Department
of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States
| |
Collapse
|